We found that SMARCB1-deficient cell lines were significantly more sensitive (two-tailed t-test p-value=0.011) to treatment with MLN2238 than non-multiple myeloma CCLE cell lines (Figure 4a; Figure 4—source data 1) (Rees et al., 2016; Seashore-Ludlow et al., 2015). Here, SMARCB1 is linked to plasma cell myeloma.